Baird analyst Joel Beatty lowered the firm’s price target on Larimar Therapeutics (LRMR) to $7 from $10 and keeps an Outperform rating on the shares. The firm updated its model to reflect increased safety and regulatory risk following the company’s Nomla update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LRMR:
- Buy Rating for Larimar Therapeutics Driven by Promising Data and Unmet Need in Friedreich’s Ataxia
- EA acquired in go-private deal for $55B, Carnival reports Q3 beat: Morning Buzz
- Optimistic Buy Rating for Larimar Therapeutics Amid Promising Data and Safety Adjustments
- Larimar Therapeutics Announces Positive Study Results
- Larimar announces 25 mg, 50 mg data from OL study of nomlabofusp